Skip to main content
SpringerLink
Log in

Acarbose treatment in obesity: a controlled study

  • Brief Report and New Hypotheses
  • Published:
Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity Aims and scope Submit manuscript

Abstract

Acarbose is an alpha-glucosidase inhibitor which reversibly inhibits oligosac charidase and disaccharidase at the brush border of the small intestine. The aim of this study was to observe its effectiveness in the treatment of obesity. Methods: Two groups o 25 obese women were put on a 15 kcal/kg/day low-calorie diet for 12 weeks. One group (the study group) received 150 mg/day acarbose for the first 2 weeks and 300 mg/day acarbose for the remaining 10 weeks. The second group (controls) received no additional treatment. Body weight, BMI, skinfold thickness, serum lipids, OGTT, and insulin and C-peptide responses to OGTT were assessed before and after the study. Results: Body weight, BM and skinfold thickness decreased significantly in both groups. Basal insulin and triglyceride levels in the study group, total and LDL cholesterol and triglyceride levels in the contro group decreased significantly. No difference was found between the two groups when these decrements were compared, but the triglyceride level fell more in the control group Conclusion: Additional acarbose therapy is not more beneficial than low-calorie diet therapy alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gray D.S.: Diagnosis and prevalence of obesity. Med. Clin. North Am., 73, 1–13, 1989.

    CAS  PubMed  Google Scholar 

  2. NIH Tecnology Assessment Conference Panel. Methods for voluntary weight loss and control. Ann. Intern. Med. 119, 764, 1993.

    Article  Google Scholar 

  3. Hodge A.M., Zimmet P.Z.: The epidemiology of obesity. Baillieres Clin. Endocrinol. Metab., 8, 577–599, 1994.

    Article  CAS  PubMed  Google Scholar 

  4. Bray G.A., Ryan D.H.: Drugs used in the treatment of obesity. Diabetes Reviews, 5, 83–103, 1997.

    Google Scholar 

  5. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med., 329, 977–986, 1993.

    Article  Google Scholar 

  6. Defronzo R.A., Ferrannini E.: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care, 14, 173–194, 1991.

    Article  CAS  PubMed  Google Scholar 

  7. Moller D.E., Flier J.S.: Insulin resistancemechanisms, syndromes and implications. N. Engl. J. Med., 325, 938–948, 1991.

    Article  CAS  PubMed  Google Scholar 

  8. Clissold S.P., Edwards C.: Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 35, 214–243, 1988.

    Article  CAS  PubMed  Google Scholar 

  9. Maggio C.A., Vasselli J.R.: Satiety in the obese Zucker rat: effects of carbohydrate type and acarbose (Bay g 5421). Physiol. Behav., 46, 557–560, 1989.

    Article  CAS  PubMed  Google Scholar 

  10. Couet C., Ulmer M., Hamdaoui M., Bau H.M., Debry G.: Metabolic effects of acarbose in young healthy men. Eur. J. Clin. Nutr., 43, 187–196, 1989.

    CAS  PubMed  Google Scholar 

  11. William-Olsson T.: Alpha-glucosidase inhibition in obesity. Acta Med. Scand., 706, 1–39, 1985.

    CAS  Google Scholar 

  12. William-Olsson T., Krotkiewski M., Sjöström L.: Relaps reducing effects of acarbose after weight reduction in severely obese subjects. J. Obes. Weight Regulation, 4, 20–32, 1985.

    Google Scholar 

  13. Goto Y., Toyoda T., Okiawa S., Moruhama Y., Tamura M., et al.: Long term administration of BAY g 5421 (acarbose) in NIDDM. Yakuri to Chiryo, 17, 387–401, 1989.

    Google Scholar 

  14. Goto Y., Nakagawa S., Goto Y., Ikeda Y., Hosoya N., et al.: Utility of BAY g 5421 (acarbose) on NIDDM, multicentre open study. Kiso to Rinsho, 23, 219–239, 1989.

    Google Scholar 

  15. Sakamoto N., Shibata M., Hotta N., Kakuta H., Tomita A., et al.: Clinical study on BAY g 5421 (acarbose) for non-insulin-dependent diabetes mellitus (NIDDM). Yakuri to Chiryo, 17, 633–649, 1989.

    Google Scholar 

  16. Coli P., Pea E., Lacorte M., Passaglia C., Carrai M.: Short term assessment of anthropometric indices and metabolic parameters in obese subjects treated with acarbose. Min. Med., 87, 161–170, 1996.

    CAS  Google Scholar 

  17. Fried S.K., Maggio C.A., Vasselli J.R.: Effets of Acarbose on Insulin Sensitivity in Adipocytes from Lean and Obese Zucker and Zucker Diabetic Fatty rats. Drugs in Development. Vol. 1 In: Vasselli J.R., Maggio C.A., Scriabine A. (Eds.), Alfa-glucosidase inhibition: Potential use in Diabetes. Neva Press, Branford, Connecticut, 1993, pp. 85–93.

    Google Scholar 

  18. Vasselli J.R., deCarr L.B., Velazquez N.: Effects of Alfa-Glucosidase Inhibition on Lipid and Lipoprotein Metabolism in Normal and Insulin-Deficient Diabetic Rats. Drugs in Development Vol. 1 In: Vasselli J.R., Maggio C.A., Scriabine A. (Eds.), Alfa-glucosidase inhibition: Potential use in Diabetes. Neva Press, Branford, Connecticut, 1993, pp. 125–131.

    Google Scholar 

  19. Abdollahi A., Tulp O.L., Schnitzer-Polokoff R.: The effects of Acarbose on Cholesterogenesis in Obese and obese-Diabetic Rats. Drugs in Development Vol. 1 In: Vasselli J.R., Maggio C.A., Scriabine A. (Eds.), Alfa-glucosidase inhibition: Potential use in Diabetes. Neva Press, Branford, Connecticut, 1993, pp. 133–143.

    Google Scholar 

  20. Hotta N., Kaluta H., Sano T., Matsumae H., Yamada H. et al.: Long term effect of acarbose on glycaemic control in non-insulin dependent diabetes mellitus: a placebo controlled double blind study. Diab. Med., 10, 134–138, 1993.

    Article  CAS  Google Scholar 

  21. Hoffmann J.: Acarbose and glibenclamid in type II-diabetes. A comparative study on efficacy and side effects. In German, Münchener Medizinishe Wochenschrift, 132, 487–490, 1990.

    Google Scholar 

  22. Bayraktar F., Yilmaz C., Ozgen A.G., Kabalak T., Tüzün M., Hamulu F.: Initial results of acarbose treatment in diabetes mellitus. Ulusal Endokrinoloji Dergisi, 4, 47–59, 1994.

    Google Scholar 

  23. deLivia A., Pinon P., Tebar J., Escobar-Jimenez F., deLivia A., de la Calle H., et al.: Efficacia clinica y tolerancia de la acarbose en el tratamiento de pacientes diabeticos no depentientes de la insulina (tipo II). Med. Clin. (Barcelona), 100, 368–371, 1993.

    Google Scholar 

  24. Goto Y., Nakagawa S., Goto Y., Hosoya Y., Orishige H. et al.: Clinical utility of BAY g 5421 (acarbose) on NIDDM. Multicentre double-blind comparative study. Igaku no Ayumi, 149, 591–618, 1989.

    Google Scholar 

  25. Rodier M., Richard J.L., Monnier L., Mirouze J.: Effect of long term acarbose (Bay 5421) therapy on metabolic control of non-insulin dependent diabetes (type II) mellitus. Diab. Metab. 14, 12–14, 1988.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology Department, University Medical Faculty, Bornova, Izmir, 35100, Turkey

    Firat Bayraktar M.D., F. Hamulu, A. G. Özgen, C. Yilmaz, M. Tüzün & T. Kabalak

Authors
  1. Firat Bayraktar M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Hamulu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. G. Özgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Tüzün
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Kabalak
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bayraktar, F., Hamulu, F., Özgen, A.G. et al. Acarbose treatment in obesity: a controlled study. Eat Weight Disord 3, 46–49 (1998). https://doi.org/10.1007/BF03339987

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03339987

Key words

Search

Navigation